A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD

Chudy-Onwugaje KO1, Christian KE1, Farraye FA2, Cross RK1. Inflamm Bowel Dis. 2018 Nov 15. doi: 10.1093/ibd/izy327. [Epub ahead of print]

Author information

1 Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.

2 Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts.


Over the last 2 decades, novel therapies targeting several immune pathways have been developed for the treatment of patients with inflammatory bowel disease (IBD). Although anti-tumor necrosis factor (anti-TNF) agents remain the firstline treatment for moderate to severe Crohn's disease and ulcerative colitis, many patients will require alternative agents, due to nonresponse, loss of response, or intolerance of anti-TNFs. Furthermore, patients may request newer therapies due to improved safety profiles or improved administration (ie, less frequent injection, oral therapy). This review will focus on new and emerging therapies for the treatment of IBD, with a special focus on their adverse effects. Although many of the agents included in this paper have been approved for use in IBD, a few are still in development but have been shown to be effective in phase II clinical trials.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.